Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.34 USD | +4.69% | -8.22% | +32.67% |
May. 15 | Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating | MT |
Mar. 04 | Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 78.86M |
---|---|---|---|---|---|
Net income 2024 * | -69M | Net income 2025 * | -82M | EV / Sales 2024 * | - |
Net cash position 2024 * | 59.7M | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.19
x | P/E ratio 2025 * |
-1.91
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.47% |
Latest transcript on Passage Bio, Inc.
1 day | +4.69% | ||
1 week | -10.67% | ||
Current month | +3.88% | ||
1 month | +8.94% | ||
3 months | +1.52% | ||
6 months | +113.55% | ||
Current year | +32.67% |
Managers | Title | Age | Since |
---|---|---|---|
William Chou
CEO | Chief Executive Officer | 51 | 22-10-09 |
James M. Wilson
FOU | Founder | - | 17-06-30 |
Director of Finance/CFO | 48 | 21-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Maxine Gowen
CHM | Chairman | 66 | 21-02-17 |
Saqib Islam
BRD | Director/Board Member | 54 | 19-03-28 |
Director/Board Member | 52 | 20-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 1.34 | +4.69% | 117,807 |
24-05-15 | 1.28 | -3.40% | 71,668 |
24-05-14 | 1.325 | -10.47% | 131,504 |
24-05-13 | 1.48 | +0.68% | 32,392 |
24-05-10 | 1.47 | +0.68% | 60,663 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.67% | 78.86M | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- PASG Stock